^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Cutaneous Melanoma
    Drug:JQ-1 (BET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Oncotarget
    Title:

    BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells

    Excerpt:
    Viability of BRAF-mutant cutaneous melanoma cells (SK-Mel19 and SK-Mel29) was assayed after 4 days of exposure to increasing doses of JQ1 treatments....The cell lines SK-Mel19 and SK-Mel29, carrying BRAFV600E mutation, showed sensitivity to JQ1 in viability assays (Figure ​(Figure5A)5A) similar to UM Gnaq-mutant cells, with IC50 of 125–500 nM.
    DOI:
    10.18632/oncotarget.5179